1. Volume 150, Issue 3, Pages 527-533 (September 2018)
Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials 
Nicola S. Meagher, Klaus Schuster, Andreas Voss, Timothy Budden, Chi Nam Ignatius Pang, Anna deFazio, Susan J. Ramus, Michael L. Friedlander 
Gynecologic Oncology 
Volume 150, Issue 3, Pages (September 2018)
DOI: /j.ygyno
Copyright © 2018 The Authors Terms and Conditions

2. Fig. 1
a: Hotspot mutation frequencies in mucinous borderline and MO-CUPs
* Indicates statistically significant difference between borderline and invasive cases (p < 0.05)
b: Immunohistochemistry gene expression patterns in mucinous borderline and MO-CUPs
* Indicates statistically significant difference (p < 0.05).
Gynecologic Oncology  , DOI: ( /j.ygyno )
Copyright © 2018 The Authors Terms and Conditions

3. Fig. 2 Key mutation frequencies compared with data from AACR GENIE
* Indicates statistically significant difference between GENIE dataset compared to this study cohort (p < 0.05).
No data available: HER2 amplification, PTEN in appendiceal and pancreas; BRAF in appendiceal.
Pancreatic tumors were Intraductal papillary mucinous neoplasm (IPMN).
^n = 240 (Current study, HER2 amplification).
Gynecologic Oncology  , DOI: ( /j.ygyno )
Copyright © 2018 The Authors Terms and Conditions